Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 9/20 | 0.53 |
| ▸ | CYP11B2 | P19099 | 9/20 | 0.53 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.51 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.41 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20519101 | 1.00 | CYP11B1 (0.53) | CYP11B1CYP11B2MAP4K1TBXAS1HSP90AA1 | |
| SCHEMBL30107166 | 0.90 | CYP11B1 (0.51) | CYP11B1CYP11B2MAP4K1HSP90AA1HSP90AB1 | |
| SCHEMBL20519343 | 0.90 | CYP11B1 (0.51) | CYP11B1CYP11B2MAP4K1HSP90AA1HSP90AB1 | |
| SCHEMBL21334717 | 0.76 | MAP4K1 (0.67) | CYP11B1CYP11B2MAP4K1 | |
| SCHEMBL20519697 | 0.76 | MAP4K1 (0.67) | CYP11B1CYP11B2MAP4K1 | |
| SCHEMBL20518941 | 0.75 | MAP4K1 (0.76) | MAP4K1 | |
| SCHEMBL21334814 | 0.75 | MAP4K1 (0.76) | MAP4K1 | |
| SCHEMBL2359239 | 0.70 | MAPT (0.56) | — | |
| SCHEMBL2359242 | 0.70 | MAPT (0.56) | — | |
| SCHEMBL23535858 | 0.70 | CYP11B2 (0.58) | CYP11B1CYP11B2HSP90AA1HSP90AB1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11034692-B1 | Naphthyridines as inhibitors of HPK1 | GENENTECH, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-10407424-B2 | Naphthyridines as inhibitors of HPK1 | GENENTECH, INC. (US) | 2019-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407424-B2 | Naphthyridines as inhibitors of HPK1 | NEK1, NEK5, NEK11 | CYP11B1 3240/4885CYP11B2 3373/4885MAP4K1 59/4885 |
| US-11034692-B1 | Naphthyridines as inhibitors of HPK1 | NEK1, NEK5, NEK11 | CYP11B1 3240/4885CYP11B2 3373/4885MAP4K1 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.